AstraZeneca (AZN) — Upcoming Catalysts
FDA PDUFA dates, advisory-committee meetings, and Phase 2/3 readout windows for AstraZeneca, built from public data lanes (ClinicalTrials.gov and official sources). Each row links to its source.
For informational purposes only — not investment advice. Track AZN live on Mooboard →
This week6
- Sep 26, 2026ClinicalTrials.gov ↗AstraZeneca(AZN)Phase 2/3 readoutZibotentan/Dapagliflozin · Phase 2 · Chronic Kidney Disease With High ProteinuriaNCT06942910: A Study to Investigate the Effects of Zibotentan/Dapagliflozin Combination Compared to Dapagliflozin Alone in Adult Participants With Chronic Kidney Disease and High Proteinuria. Primary completion 2026-09-26 (estimated); status ACTIVE_NOT_RECRUITING.
- Sep 28, 2026ClinicalTrials.gov ↗AstraZeneca(AZN)Phase 2/3 readoutAZD0901 · Phase 2 · Gastric Cancer; Gastroesophageal Junction CancerNCT07143604: A Study to Investigate the Effects of AZD0901 Monotherapy in Adult Participants With 2L+ Advanced or Metastatic Gastric or GEJ Adenocarcinoma Expressing CLDN18.2. Primary completion 2026-09-28 (estimated); status ACTIVE_NOT_RECRUITING.
- Sep 30, 2026ClinicalTrials.gov ↗AstraZeneca(AZN)Phase 2/3 readoutPlacebo · Phase 2 · DyslipidaemiaNCT07218900: A Study to Investigate the Effect of AZD0780 Tablets in Combination With Rosuvastatin Tablets on Low Density Lipoprotein Cholesterol Levels (LDL-C) in Adult Participants With Dyslipidaemia. Primary completion 2026-09-30 (estimated); status ACTIVE_NOT_RECRUITING.
- Sep 30, 2026ClinicalTrials.gov ↗AstraZeneca(AZN)Phase 2/3 readoutDurvalumab · Phase 3 · Hepatocellular CarcinomaNCT05557838: Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With uHCC. Primary completion 2026-09-30 (estimated); status ACTIVE_NOT_RECRUITING.
- Sep 30, 2026ClinicalTrials.gov ↗AstraZeneca(AZN)Phase 2/3 readoutDurvalumab · Phase 3 · Non-Small Cell Lung CancerNCT05221840: A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer. Primary completion 2026-09-30 (estimated); status ACTIVE_NOT_RECRUITING.
- Sep 30, 2026ClinicalTrials.gov ↗AstraZeneca(AZN)Phase 2/3 readoutDato-DXd · Phase 3 · Metastatic Non-small Cell Lung CancerNCT06417814: A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer. Primary completion 2026-09-30 (estimated); status RECRUITING.
Next 30 days2
- Oct 7, 2026ClinicalTrials.gov ↗AstraZeneca(AZN)Phase 2/3 readoutAZD6489 · Phase 1 / Phase 2 · RSV Respiratory Syncytial VirusNCT07717840: A Study to Characterize the Safety and Immunogenicity of AZD6489 in Participants 60 Years of Age and Older (ARIES). Primary completion 2026-10-07 (estimated); status ACTIVE_NOT_RECRUITING.
- Oct 23, 2026ClinicalTrials.gov ↗AstraZeneca(AZN)Phase 2/3 readoutDurvalumab · Phase 2 · Carcinoma, Non-Small-Cell LungNCT06008093: A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS. Primary completion 2026-10-23 (estimated); status ACTIVE_NOT_RECRUITING.
31–90 days8
- Oct 27, 2026ClinicalTrials.gov ↗AstraZeneca(AZN)Phase 2/3 readoutVolrustomig · Phase 2 · Hepatocellular Carcinoma; Biliary Tract CancerNCT05775159: Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer. Primary completion 2026-10-27 (estimated); status ACTIVE_NOT_RECRUITING.
- Oct 31, 2026ClinicalTrials.gov ↗AstraZeneca(AZN)Phase 2/3 readoutCapivasertib · Phase 3 · Breast CancerNCT06635447: Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients. Primary completion 2026-10-31 (estimated); status ACTIVE_NOT_RECRUITING.
- Nov 2, 2026ClinicalTrials.gov ↗AstraZeneca(AZN)Phase 2/3 readoutAnifrolumab · Phase 3 · Cutaneous Lupus ErythematosusNCT06015737: A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus. Primary completion 2026-11-02 (estimated); status ACTIVE_NOT_RECRUITING.
- Nov 11, 2026ClinicalTrials.gov ↗AstraZeneca(AZN)Phase 2/3 readoutTrastuzumab deruxtecan · Phase 3 · Breast Cancer; HER2-positive; MetastaticNCT04784715: Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09). Primary completion 2026-11-11 (estimated); status ACTIVE_NOT_RECRUITING.
- Nov 17, 2026ClinicalTrials.gov ↗AstraZeneca(AZN)Phase 2/3 readoutAZD0901 · Phase 2 · Gastric Cancer; Gastroesophageal Junction CancerNCT06219941: AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2. Primary completion 2026-11-17 (estimated); status RECRUITING.
- Nov 24, 2026ClinicalTrials.gov ↗AstraZeneca(AZN)Phase 2/3 readoutAZD0754 · Phase 1 / Phase 2 · Metastatic Prostate CancerNCT06267729: Study of AZD0754 in Participants With Metastatic Prostate Cancer. Primary completion 2026-11-24 (estimated); status RECRUITING.
- Nov 30, 2026ClinicalTrials.gov ↗AstraZeneca(AZN)Phase 2/3 readoutDurvalumab · Phase 2 · Hepatocellular CarcinomaNCT07081633: Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma. Primary completion 2026-11-30 (estimated); status ACTIVE_NOT_RECRUITING.
- Dec 10, 2026ClinicalTrials.gov ↗AstraZeneca(AZN)Phase 2/3 readoutBaxdrostat/dapagliflozin · Phase 2 · Chronic Kidney Disease and HypertensionNCT07222917: A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure.. Primary completion 2026-12-10 (estimated); status ACTIVE_NOT_RECRUITING.
Later9
- Dec 31, 2026ClinicalTrials.gov ↗AstraZeneca(AZN)Phase 2/3 readoutDurvalumab · Phase 3 · CancerNCT05303532: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab. Primary completion 2026-12-31 (estimated); status ENROLLING_BY_INVITATION.
- Jan 4, 2027ClinicalTrials.gov ↗AstraZeneca(AZN)Phase 2/3 readoutAZD0780 · Phase 3 · Heterozygous Familial HypercholesterolaemiaNCT07000136: A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With HeFH. Primary completion 2027-01-04 (estimated); status ACTIVE_NOT_RECRUITING.
- Jan 6, 2027ClinicalTrials.gov ↗AstraZeneca(AZN)Phase 2/3 readoutPlacebo (blinded) · Phase 3 · Systemic Sclerosis; SclerodermaNCT05925803: Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY). Primary completion 2027-01-06 (estimated); status ACTIVE_NOT_RECRUITING.
- Jan 11, 2027ClinicalTrials.gov ↗AstraZeneca(AZN)Phase 2/3 readoutAZD0780 · Phase 3 · Cardiovascular DiseaseNCT07000123: A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event. Primary completion 2027-01-11 (estimated); status ACTIVE_NOT_RECRUITING.
- Jan 13, 2027ClinicalTrials.gov ↗AstraZeneca(AZN)Phase 2/3 readoutTezepelumab · Phase 3 · Chronic Rhinosinusitis With Nasal PolypsNCT06706817: A Study to Investigate Changes in Symptoms in Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis Initiating Treatment With Tezepelumab. Primary completion 2027-01-13 (estimated); status ACTIVE_NOT_RECRUITING.
- Jan 18, 2027ClinicalTrials.gov ↗AstraZeneca(AZN)Phase 2/3 readoutSavolitinib · Phase 2 · Lung CancerNCT05374603: Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLC. Primary completion 2027-01-18 (estimated); status ACTIVE_NOT_RECRUITING.
- Jan 29, 2027ClinicalTrials.gov ↗AstraZeneca(AZN)Phase 2/3 readoutAZD9550 · Phase 1 / Phase 2 · Overweight and ObesityNCT06151964: A Trial to Learn How Safe AZD9550 Monotherapy and Combined With AZD6234 is in People With or Without Type 2 Diabetes Who Are Living With Obesity and Overweight. Primary completion 2027-01-29 (estimated); status ACTIVE_NOT_RECRUITING.
- Feb 10, 2027ClinicalTrials.gov ↗AstraZeneca(AZN)Phase 2/3 readoutTrastuzumab deruxtecan · Phase 2 · Advanced Solid Tumors (Excluding Gastric Cancer and Breast Cancer)NCT06271837: A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors. Primary completion 2027-02-10 (estimated); status ACTIVE_NOT_RECRUITING.
- Feb 11, 2027ClinicalTrials.gov ↗AstraZeneca(AZN)Phase 2/3 readoutAZD4144 · Phase 2 · Sepsis; Acute Kidney InjuryNCT07215702: A Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kidney Injury.. Primary completion 2027-02-11 (estimated); status RECRUITING.
How AstraZeneca has moved — past-year price reactions
How binary is AZN? Its typical daily move, how often it swings ±10%, and its biggest single-day moves over the last year — useful context for sizing around a catalyst.
1.1%
0
28.6%
249
Largest single-day moves
- +10%2025-10-01no matched headline
- -6.9%2026-08-03no matched headline
- +6.1%2026-07-02no matched headline
- +5.9%2026-02-11no matched headline
- -5.7%2026-07-09no matched headline
- -4.7%2026-01-20no matched headline
Real daily price moves over the past year — not every move is a catalyst, and headlines (where shown) are a possible same-day driver, not confirmed causation.
AstraZeneca — active clinical pipeline
AstraZeneca's registered Phase 1–3 programs by asset and indication, derived from ClinicalTrials.gov.
79 assets133 programsPh1 22Ph2 50Ph3 58· 3 post-marketing (Ph4)
AreasOncologyAutoimmuneImmunologyMetabolicNeuroscienceCardiovascularInfectiousRare / GeneticOther
DurvalumabOncology · PD-L1
Phase 2
VolrustomigOncology
Trastuzumab deruxtecanOncology · HER2 ADC
Phase 2
AZD6234Metabolic
Phase 1
Phase 3
AnifrolumabAutoimmune · IFNAR
AZD9833Oncology
capivasertibOncology · AKT2
OsimertinibOncology · EGFR
Phase 3
RilvegostomigOncology
SelumetinibOncology
Phase 1
TezepelumabImmunology · TSLP
AcalabrutinibOncology · BTK
FulvestrantOncology · ER
OlaparibOncology · PARP
Zibotentan/DapagliflozinOther
AZD9291 80 mg/40 mgOncology
BaxdrostatOther
Phase 3
BenralizumabAutoimmune · IL-5Rα
BevacizumabOncology
Phase 3
Dato-DXdOncology · TROP2 ADC
Phase 3
Durvalumab (MEDI4736)Oncology · PD-L1
Durvalumab +TremelimumabOncology
MonalizumabOncology
Olaparib 300mg tabletsOther · PARP
Phase 3
Rosuvastatin 1Other
Phase 3
SaruparibOncology
Phase 3
Saruparib (AZD5305)Oncology
Phase 3
TozorakimabInfectious
Tozorakimab Dose Regimen 1Other
TremelimumabOncology
Phase 3
SurovatamigOncology
AZD0292Other
AZD0305Oncology
Phase 2
AZD2936Oncology
AZD3470Oncology
Phase 2
AZD3632Other
AZD4045Oncology
AZD4144Infectious
Phase 2
AZD4360Oncology
Phase 2
AZD4956Oncology
Phase 2
AZD5148Infectious
AZD5305Oncology
Phase 2
AZD5863Oncology
Phase 2
AZD6489Infectious
AZD6793Immunology
AZD7798Autoimmune
AZD8205Oncology
Phase 2
AZD8359Oncology
Phase 2
AZD8965 low doseOther
AZD9574Oncology
Phase 2
CamizestrantOncology · ER
Phase 2
Datopotamab deruxtecan (Dato-DXd)Oncology · TROP2 ADC
Phase 2
EplontersenRare / Genetic
Fluorouracil (5-FU)Oncology
Phase 2
Olaparib Continuous (28-Day cycle) 300 mg BD.Oncology
OleclumabOncology · NT5E
Phase 2
Osimertinib 80 mg/40 mgOncology · EGFR
Torvutatug samrotecanOncology
Phase 2
Administration of ceralasertibOncology
AZD0120 - Regimen 1Neuroscience
Phase 1
AZD0486 IVOncology
Phase 1
AZD1613Other
Phase 1
AZD1705Cardiovascular
Phase 1
AZD2962Oncology
Phase 1
AZD4063Cardiovascular
Phase 1
AZD4954Metabolic
Phase 1
Balcinrenone/dapagliflozinOther
Phase 1
cediranibOncology · VEGFR1/KIT/PDGFRβ
Phase 1
Elecoglipron Reference Formulation Dose AOther
Phase 1
SC durvalumab + rHuOncology
Phase 1
Active registered Phase 1–3 trials from ClinicalTrials.gov — not the company's official IR pipeline (no preclinical or undisclosed assets). Grouped by trial intervention name; therapeutic area is auto-categorized. Each indication links to its trial. Molecular targets sourced from ChEMBL (EMBL-EBI).
Targets from a ChEMBL (EMBL-EBI) snapshot dated 2026-08-20 · 310/1701 assets resolved when it was built
See the full biopharma catalyst calendar across all covered companies.